Vaginal atrophy & GSM assessment and treatment
Vaginal Atrophy & GSM Assessment and Treatment for Dryness, Burning, Painful Intimacy, Urinary Urgency & Recurrent UTI-Like Symptoms
Quick answer
Vaginal atrophy is now often called genitourinary syndrome of menopause, or GSM. It describes low-oestrogen changes affecting the vulva, vagina, bladder and urinary tract. Symptoms can include dryness, soreness, burning, painful sex, urinary urgency and recurrent UTI-like symptoms. Treatment is tailored after assessment.
GSM is not “just dryness”. It can affect daily comfort, clothing tolerance, exercise, sleep, intimacy, bladder confidence and emotional wellbeing. Some women notice dryness first. Others notice urinary urgency, repeated cystitis-like symptoms, burning, soreness or pain with intimacy.
The safest approach is to confirm what is driving symptoms before choosing treatment. We review menopause status, breastfeeding, surgical menopause, cancer treatment, medication, recurrent infection history, vulval symptoms, urinary symptoms and whether any red flags need investigation first.
Treatment may include vaginal moisturisers, lubricants, vaginal oestrogen where suitable, HA hydration, RF, PRP, Nu-V / fractional CO₂ laser, labia majora filler, vulval tightening or selected regenerative options. We explain what is established, what is emerging and what is not appropriate for you.
Educational only. Results vary. Not a cure. A consultation is required to confirm diagnosis, suitability, risks and the safest treatment pathway.
At a glance
A clear overview of how we assess and treat vaginal atrophy / GSM without assuming one treatment fits everyone.
Common symptoms
Dryness, burning, soreness, pain, urinary urgency or recurrent UTI-like flares.
Possible drivers
Menopause, surgical menopause, breastfeeding, cancer treatment or anti-oestrogen medication.
Established options
Moisturisers, lubricants and vaginal oestrogen where clinically suitable.
Clinic options
Nu-V / CO₂ laser, RF, PRP, HA hydration, exosomes or filler in selected cases.
Reviews
Experiences shared by women like you
Real feedback from women who felt listened to, supported and cared for throughout their journey.
Fantastic service by everyone. I could talk openly without feeling embarrassed, and everything was explained clearly. The team made me feel so comfortable and at ease.
Finally, a place that explains everything fully. The staff put my mind at ease and I felt listened to, understood, and given sound advice.
Katy went above and beyond making me feel comfortable and making sure I understood everything that was happening and what to expect. Very nice and clean facilities.
GSM often affects more than one part of life
These are the kinds of symptoms and concerns women commonly raise in consultation.
“
It feels dry, sore or burning even when I am not sexually active.
“
Intimacy has become painful, so I have started avoiding it.
“
I keep getting urgency or UTI-like symptoms and I did not realise GSM could be involved.
“
I want to understand hormonal and non-hormonal options clearly before deciding.
These are representative concerns commonly discussed in consultations, not individual verified patient reviews.
Treatment pathway
Start with diagnosis and symptom pattern, then choose the right option
GSM treatment may involve established medical options, non-hormonal moisturisers, local hydration, energy-based treatment or regenerative options. The best pathway depends on symptoms, medical history, cancer history, medication, urinary symptoms and personal preference.
Indicative prices
Treatment prices from
Prices are shown as a broad guide only. Final treatment choice depends on consultation, diagnosis, symptoms, examination findings, medical history, suitability and your preferences.
Nu-V / CO₂ laser
From £599
Nurse-led; doctor-led from £799.
Laser course of 3
From £1,200
Doctor-led from £1,800.
HA hydration booster
From £795
Course of 2 from £1,400.
PRP / RF options
From £699
Suitability assessed individually.
Prices are indicative and subject to change. Treatment planning and suitability are confirmed after consultation and assessment.
Helpful videos on GSM, vaginal atrophy and treatment choices
These videos support the page by explaining related symptoms, treatment choices and what to consider before deciding on a pathway.
Can untreated vaginal atrophy cause prolapse? | WHC Clinical FAQ
What are the common symptoms of vaginal atrophy (GSM)? | WHC Clinical FAQ
What is the difference between vaginal atrophy and vaginal dryness? | WHC Clinical FAQ
What is vaginal atrophy and how does it cause dryness? | WHC Clinical FAQ
Can vaginal atrophy cause chronic pelvic pain? | WHC Clinical FAQ
Before treatment, we confirm the symptom pattern and rule out red flags
Vaginal atrophy and GSM can overlap with infection, vulval skin conditions, pelvic floor tension, bladder sensitivity and recurrent UTI-like symptoms. A careful assessment helps decide whether you need moisturisers, vaginal oestrogen, non-hormonal treatment, regenerative options or further medical review.
We review dryness, burning, soreness, painful intimacy, urinary urgency, recurrent UTI-like symptoms, vaginal or vulval discomfort, menopause status, breastfeeding, surgical menopause, cancer treatment history, medication and previous treatments tried.
Your plan may include moisturisers, lubricants, vaginal oestrogen where suitable, HA hydration, RF, PRP, Nu-V / fractional CO₂ laser, labia majora support, vulval tightening or selected regenerative options — but only after suitability and safety checks.
Vaginal symptoms
Dryness, soreness, burning, irritation, tightness or pain with intimacy.
Urinary symptoms
Urgency, frequency, recurrent UTI-like flares or burning when urine touches sensitive tissue.
Treatment context
Menopause, breastfeeding, surgical menopause, cancer treatment or anti-oestrogen medication.
Safety checks
Bleeding, infection, lesions, cancer history, radiotherapy or pregnancy may change the pathway.
How we assess vaginal atrophy and GSM before recommending treatment
GSM is common, but symptoms should still be assessed properly. Dryness, burning, recurrent UTI-like symptoms or pain can have more than one cause, and treatment should be matched to the clinical picture.
We take a stepwise approach: understand symptoms, check safety, identify the likely driver, then explain established and emerging options clearly.
Step 1
Symptom mapping
We ask about dryness, burning, soreness, itching, tearing, pain with intimacy, reduced lubrication, urinary urgency, recurrent UTIs and daily discomfort.
Step 2
Life-stage and hormone context
We consider menopause, perimenopause, breastfeeding, surgical menopause, cancer treatment, anti-oestrogen medication and other causes of low-oestrogen symptoms.
Step 3
Sensitive examination where appropriate
With consent, examination can help assess tissue thinning, fragility, narrowing, tenderness, vulval skin changes, infection signs or pelvic floor guarding.
Step 4
Rule out infection and red flags
Active infection, unexplained bleeding, new lesions, abnormal discharge, suspected malignancy or severe pain should be assessed before elective treatment.
Step 5
Discuss established options
Moisturisers, lubricants and vaginal oestrogen where suitable are discussed as important foundations, especially for menopausal GSM.
Step 6
Consider selected step-up options
HA hydration, RF, PRP, Laser or regenerative options may be discussed where suitable, with clear evidence, risk and expectation counselling.
Treatment should not be guessed
GSM can look like dryness, urinary symptoms, recurrent cystitis or painful intimacy
The right plan depends on which symptoms are dominant, what has already been tried, whether hormones are suitable, and whether any red flags need investigation first.
What is vaginal atrophy or genitourinary syndrome of menopause?
Vaginal atrophy describes low-oestrogen tissue changes that can make the vaginal and vulval tissues thinner, drier, more fragile and less elastic. The wider term GSM is often used because symptoms can also affect the bladder, urethra and urinary tract.
GSM can occur with natural menopause, perimenopause, surgical menopause, breastfeeding, cancer treatment, pelvic radiotherapy or anti-oestrogen medication. Symptoms may be gradual or sudden depending on the cause.
Vaginal and vulval symptoms
Dryness, burning, soreness, itching, stinging, splitting, reduced lubrication or pain with intimacy can all be part of GSM.
Urinary symptoms
Low-oestrogen changes can contribute to urinary urgency, frequency, recurrent UTI-like symptoms or burning when urine touches sensitive tissue.
Daily life and intimacy
GSM can affect clothing comfort, exercise, sleep, confidence, sexual comfort and relationships. These symptoms are valid and treatable.
Why GSM can be progressive
Unlike some menopause symptoms that may ease over time, low-oestrogen tissue changes often persist or worsen without ongoing support. Tissue may become drier, thinner, more fragile and more prone to irritation.
Natural menopause
GSM is common after menopause as oestrogen levels reduce and tissue support changes.
Breastfeeding
Breastfeeding can create a temporary low-oestrogen state that may cause dryness or discomfort.
Surgical menopause
Ovarian removal can cause sudden oestrogen loss, often with more abrupt symptoms.
Cancer treatment
Chemotherapy, pelvic radiotherapy or anti-oestrogen medication can contribute to GSM symptoms.
Why urinary symptoms can be part of GSM
The urethra, bladder base, vulva and vagina are all influenced by low-oestrogen tissue change. That is why some women experience urgency, frequency or recurrent UTI-like symptoms alongside dryness or soreness.
Medical note: postmenopausal bleeding, unexplained bleeding, new lesions, persistent pain, active infection or suspected malignancy should be medically assessed before elective GSM treatment.
Who may benefit from vaginal atrophy / GSM assessment?
This pathway is for women with persistent dryness, soreness, urinary symptoms or painful intimacy who want a clear, medical explanation and treatment plan.
Menopause and perimenopause
Women experiencing dryness, soreness, burning, pain with intimacy, urgency or recurrent UTI-like symptoms around midlife.
Breastfeeding and postpartum symptoms
Women with temporary low-oestrogen symptoms during breastfeeding, especially dryness, discomfort or painful intimacy.
Surgical menopause
Women with symptoms after ovarian removal or treatment that caused a sudden drop in oestrogen.
Cancer treatment history
Women after chemotherapy, pelvic radiotherapy or anti-oestrogen treatment who need cautious hormonal or non-hormonal discussion.
Persistent symptoms despite moisturisers
Women who have tried lubricants or moisturisers but still experience ongoing soreness, dryness, pain or urinary symptoms.
Recurrent urinary symptoms
Women with recurrent UTI-like symptoms, urgency or burning where GSM may be contributing alongside infection or bladder factors.
Not every plan needs a procedure
The safest option depends on symptoms, history and suitability
Some women need local oestrogen. Some need non-hormonal comfort care. Some may consider laser, PRP, HA or RF. Some need investigation before treatment. Assessment decides the right pathway.
Vaginal atrophy and GSM treatment options
GSM treatment should be matched to the symptoms, tissue findings, medical history and whether hormonal treatment is suitable. Some women need established medical care. Others need non-hormonal or step-up options.
We explain the difference between symptom relief, established medical treatment, tissue hydration and selected regenerative or energy-based options so you can make an informed decision.
Vaginal moisturisers and lubricants
Regular moisturisers can support baseline comfort, while lubricants reduce friction during intimacy. They can be helpful, but may not fully address established GSM tissue change.
Vaginal oestrogen discussion
Vaginal oestrogen is an established option for menopausal GSM where suitable. It is designed to act locally, but cancer history, individual risk and preferences must be reviewed carefully.
Hyaluronic acid hydration booster
HA hydration may be discussed for women seeking non-hormonal tissue hydration and support. It is not the same as surface moisturiser and suitability depends on symptoms and examination.
Nu-V / fractional CO₂ laser
Laser may be discussed in selected cases where tissue change is contributing to symptoms. We explain evidence limitations, regulatory context, possible risks, aftercare and alternative options.
PRP, RF and vulval support
PRP, RF, vulval tightening or labia majora support may be discussed where symptoms, anatomy and goals match. These are not universal GSM treatments and require careful consent.
Exosomes and regenerative options
Exosomes and some regenerative approaches are discussed only with clear explanation of their investigational status, uncertainty, regulatory considerations and alternatives.
Why this stepwise approach matters
GSM can be chronic and may need ongoing maintenance. The right plan may include simple products, prescribed local treatment, a non-hormonal option or a clinic procedure. We avoid presenting any option as a guaranteed cure.
Vaginal atrophy and GSM treatment prices
Pricing depends on whether a clinic-based treatment is suitable. Some women need prescribed local treatment, moisturisers, lifestyle support or further investigation rather than a private procedure.
Prices below are indicative and subject to change. Final recommendations depend on consultation, assessment findings, symptoms, medical history, suitability and goals. Please also refer to our latest pricing page.
Before choosing treatment
Treatment choice depends on safety, symptoms and suitability
If you have unexplained bleeding, active infection, suspected malignancy, significant cancer-treatment history or pelvic radiotherapy history, treatment choice may need further medical review first.
Nu-V / fractional CO₂ laser
Nu-V laser may be discussed for selected GSM / tissue-change symptoms after clinical assessment and evidence counselling.
Nurse-led single session
£599
Indicative single-session price.
Doctor-led single session
£799
Indicative single-session price.
Nurse-led course of 3
£1,200
Indicative course pricing.
Doctor-led course of 3
£1,800
Indicative course pricing.
PRP / platelet-rich plasma
£1,110
Standalone session
£2,985
Course of 3
Hyaluronic acid hydration booster
£795
Single session
£1,400
Course of 2
Radiofrequency treatment
£699
Single session
£2,300
Course of 4
Labia majora filler and vulval tightening
Exosomes and combination package
Prices are indicative and may be updated. Final treatment planning and suitability are confirmed after consultation and assessment. Please refer to the latest WHC pricing page for current pricing.
Vaginal atrophy treatment safety, suitability and reasons to pause
GSM symptoms are common, but not every symptom should be treated as GSM without checks. Certain symptoms need investigation before elective intimate treatment.
We use a “pause and assess first” approach for bleeding, infection, suspected malignancy, pregnancy, cancer history, radiotherapy history and treatment-specific risks.
When we do not proceed on the day
Undiagnosed bleeding
Especially postmenopausal bleeding. This must be investigated before GSM procedures or assumptions are made.
Active infection
BV, thrush, STI, PID, UTI or active herpes should be assessed and treated before elective treatment.
New lesions or suspected malignancy
New lumps, ulcers, skin changes or suspected cancer require appropriate medical investigation first.
Pregnancy
Assessment may be appropriate, but elective GSM procedures are usually deferred.
Situations needing individual review
Cancer history or anti-oestrogen therapy
Especially hormone-sensitive cancer. Oncology input may be needed before hormonal or selected non-hormonal treatment planning.
Pelvic radiotherapy history
Tissue response and healing may be different. Laser, injections or energy-based treatment require extra caution.
Blood disorders or clotting issues
Relevant for PRP or injection-based options, especially low platelets, anticoagulants or bleeding risk.
Investigational treatments
Exosomes and newer regenerative options require clear explanation of uncertainty, evidence limits and regulatory context.
Evidence transparency
We separate established care from emerging options
Vaginal oestrogen has a different evidence base from laser, PRP, HA, RF or exosomes. We explain these differences clearly so you can understand benefits, uncertainty, risks, alternatives and maintenance needs.
This list is not exhaustive. Final suitability depends on symptoms, medical history, examination findings where appropriate, medication, pregnancy status, cancer history, consent, goals and the specific treatment being considered.
Frequently asked questions about vaginal atrophy and GSM treatment
These are some of the most common questions women ask when dryness, burning, painful intimacy or urinary symptoms may be linked to GSM.
We answer them clearly while keeping treatment claims realistic and evidence-aware.
Is vaginal atrophy the same as vaginal dryness?
Can urinary symptoms really be linked to GSM?
What is the most established treatment?
Is laser proven for GSM?
Can I choose a non-hormonal plan?
Can I use vaginal oestrogen after breast cancer?
How quickly will symptoms improve?
Is GSM treatment permanent?
Can treatments be combined?
What if moisturisers have not worked?
Still unsure?
Have a question that is not covered here?
GSM can feel confusing because symptoms can involve both vaginal and urinary changes. A confidential assessment can help identify the safest and most relevant pathway.
Practical self-care for vaginal atrophy and GSM symptoms
Self-care can support comfort, reduce irritation and help you understand your symptom pattern. It does not replace medical assessment, especially if symptoms are persistent, worsening or include bleeding, infection signs or new skin changes.
The most useful routine is usually regular, gentle and symptom-led rather than relying on one product only when symptoms flare.
Use vaginal moisturisers regularly
Vaginal moisturisers are designed for baseline tissue comfort. They are different from lubricants and are usually used regularly rather than only during intimacy.
Use a suitable moisturiser consistently, often several times per week depending on the product and symptoms.
Stop any product that stings, burns or worsens irritation and seek advice.
If symptoms persist despite regular use, assessment can help decide whether step-up care is needed.
Use lubricant before friction starts
Lubricants reduce friction during intimacy. They do not treat the underlying tissue change, but they can reduce irritation and help prevent pain cycles.
Use lubricant generously and early, not only once discomfort has started.
Avoid fragranced, warming, tingling or strongly perfumed products if tissue is sensitive.
Pain with intimacy should not be pushed through. Ongoing pain needs review.
Avoid common irritants
GSM tissue can be more reactive. Removing irritants can reduce burning, stinging and flare-ups.
Avoid douching, perfumed washes, bubble baths and harsh soaps around the vulva.
Choose gentle cleansing and avoid over-washing, which can worsen dryness and irritation.
If symptoms are one-sided, severe, persistent or associated with skin changes, seek medical review.
Track urinary and flare patterns
Urinary urgency, burning and recurrent UTI-like symptoms may be linked to GSM, infection, bladder sensitivity or a combination.
Note whether symptoms are linked to intimacy, exercise, urine contact, products, dehydration or confirmed infection.
If you are repeatedly treated for UTIs, urine testing and GSM assessment can both be useful.
Blood in urine, fever, kidney pain or severe symptoms need urgent medical care.
When self-care is not enough
Persistent GSM symptoms often need a structured treatment plan
If dryness, burning, pain, urgency or recurrent UTI-like symptoms continue despite careful self-care, assessment can help decide whether prescribed local treatment, non-hormonal support or clinic-based options are appropriate.
Common myths about vaginal atrophy and GSM
GSM symptoms are often minimised or misunderstood. These myth-versus-reality cards help separate practical medical care from outdated assumptions.
The aim is not to over-medicalise every symptom. It is to make sure women are not dismissed when symptoms are persistent or affecting quality of life.
“It is just dryness.”
GSM can affect the vulva, vagina, bladder and urethra. Dryness is one symptom, but burning, pain, urinary urgency and recurrent UTI-like symptoms can also occur.
“It is just part of ageing, so nothing can be done.”
GSM is common, but it is also treatable. Options include moisturisers, lubricants, vaginal oestrogen where suitable and selected non-hormonal or clinic-based options.
“Lubricant fixes the underlying problem.”
Lubricant reduces friction during intimacy, but it does not treat tissue thinning, pH change or urinary symptoms. Many women need a broader plan.
“Only older women get GSM.”
GSM-type symptoms can also occur after surgical menopause, during breastfeeding, after cancer treatment or with anti-oestrogen medication.
“Laser or PRP are guaranteed solutions.”
Laser, PRP and other regenerative options may be discussed in selected cases, but evidence and long-term data vary. Results are not guaranteed.
“If I am aroused, dryness should not happen.”
Arousal and tissue health are related but not identical. Low-oestrogen tissues can remain dry, fragile or painful even when desire is present.
Need clarity?
GSM symptoms are valid and treatable
A careful consultation can help work out whether your symptoms are due to GSM, infection, vulval skin change, bladder issues, pelvic floor factors or a combination.
More about GSM, tissue change and treatment choices
GSM is a tissue, comfort and urinary health condition linked to low-oestrogen change. Understanding the difference between symptom relief, medical treatment and emerging procedures can help you make safer decisions.
These expandable sections give extra context for women who want to understand the science and treatment choices before consultation.
Why low oestrogen affects tissue comfort
Oestrogen helps support tissue thickness, elasticity, moisture, blood flow and the protective vaginal environment. When oestrogen falls, the tissues may become thinner, drier and more vulnerable to irritation.
This is why symptoms can include soreness, burning, splitting, painful intimacy and urinary symptoms rather than dryness alone.
Laser, RF, PRP and HA: what they are trying to do
Laser and RF
Energy-based treatments aim to create controlled tissue heating or stimulation. Evidence and long-term data vary, so counselling is essential.
PRP and HA
PRP is a biologic option using platelets. HA is a hydration-support option. Both require suitability assessment and realistic expectations.
Exosomes and investigational treatments
Why this needs careful wording
Exosomes and some regenerative approaches are evolving areas. They may be discussed only with clear explanation of uncertainty, evidence limitations, regulatory context and alternatives.
They should not be presented as established first-line GSM treatments or guaranteed outcomes.
Cancer treatment, GSM and oncology-aware care
Hormone-sensitive history
Vaginal oestrogen and other hormonal decisions may need oncology input depending on the cancer type and current treatment.
Non-hormonal discussion
Non-hormonal moisturisers, HA, PRP, RF or laser may be discussed in selected cases, but suitability still depends on tissue status and medical history.
Your rights and consent
Consent and comfort
You can pause or stop an examination or treatment at any time. A chaperone can be provided for intimate examinations.
No same-day pressure
You should never feel pressured to book a procedure on the day. A cooling-off period and second opinion are always reasonable.
Ready to ask better questions?
Understanding the options can make consultation clearer
You do not need to decide whether you need vaginal oestrogen, HA, PRP, laser or another option before booking. The consultation helps work that out.
Further support and helpful next steps
GSM can affect comfort, intimacy, urinary confidence and daily life. Symptoms are common, but they are still valid and deserve proper assessment.
These suggestions are here to support informed conversations — not to replace individual medical assessment, diagnosis or prescribing.
Useful topics to read about
Vaginal dryness and painful intimacy
Helpful if dryness, burning, friction or pain during intimacy is a dominant concern.
Recurrent UTI and urinary urgency
Helpful if urinary symptoms are part of the picture and infection testing has been repeated.
Cancer-treatment-related GSM
Helpful if symptoms followed chemotherapy, pelvic radiotherapy, ovarian suppression or hormone-blocking medication.
What to bring to consultation
Symptom pattern
Dryness, burning, soreness, pain with intimacy, itching, urinary urgency, recurrent UTI-like symptoms, bleeding or skin changes.
Medical and treatment history
Menopause status, breastfeeding, surgery, cancer treatment, pelvic radiotherapy, HRT/local oestrogen use and medication.
What you have already tried
Moisturisers, lubricants, antibiotics, vaginal oestrogen, HA products, pelvic floor care, previous procedures or anything that helped or worsened symptoms.
Reference themes
What our page is broadly guided by
GSM can affect the vulva, vagina, urethra and bladder, not just vaginal lubrication.
Established medical options, non-hormonal comfort care and selected procedures have different evidence levels.
Bleeding, infection, cancer history and pelvic radiotherapy require extra caution before treatment planning.
Next step
You do not need to decide the treatment pathway alone
If GSM symptoms are affecting comfort, intimacy, urinary confidence or daily life, the most useful next step is a structured assessment that respects your history and preferences.
Educational only. This page is designed to support informed discussion and does not replace individual medical assessment, diagnosis, prescribing, pelvic floor physiotherapy, oncology advice or urgent care. Suitability and treatment planning depend on symptoms, history, examination findings where appropriate and the specific treatment being considered.
Clinical references and further reading
This page is informed by clinical resources relevant to GSM, urogenital atrophy, vaginal oestrogen, energy-based device guidance and selected regenerative options.
1. NICE NG23
Menopause: identification and management, including genitourinary symptoms and treatment recommendations.
View source2. NICE IPG697
Transvaginal laser therapy for urogenital atrophy: interventional procedure guidance.
View source3. FDA
Safety communication on energy-based devices marketed for vaginal rejuvenation or sexual function claims.
View source4. British Menopause Society
Educational resources and consensus information on genitourinary syndrome of menopause.
View sourceEducational only. These references are provided for transparency and further reading. They do not replace individual medical assessment, diagnosis, prescribing or personalised treatment planning.
